Birth outcomes in pregnant women treated with low-molecular-weight heparin

References

• Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258–65.
   Google Scholar
• Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210–13.
   Google Scholar
• Franks AL, Atrash HK, Lawson HW, Colberg KS. Obstetrical pulmonary embolism mortality, United States, 197085. Public Health Briefs 1990; 80: 720–2.
   Google Scholar
• Andersen BS, Steffensen FH, Sørensen HT, Nielsen GL, Olsen J. The cumulative incidence of venous thromboembolism during pregnancy and puerperium. An 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand 1998; 77: 170–3.
   Google Scholar
• Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517–22.
   Google Scholar
• Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–7.
   Google Scholar
• Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004–8.
   Google Scholar
• Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133–4.
   Google Scholar
• Friederich PW, Sanson B-J, Simoni P, Zanardi S, Huisman MV Kindt I et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125: 955–60.
   Google Scholar
• Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 10: 688–98.
   Google Scholar
• Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984; 34: 557–60.
   Google Scholar
• Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular- weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176: 1062–8.
   Google Scholar
• Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652–6.
   Google Scholar
• Gillis S, Shushan A, Eldor A. Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int J Gynaecol Obstet 1992; 39: 297–301.
   Google Scholar
• Bertoli D, Borelli G. Peri- and postnatal teratology and reproductive studies of a low molecular weight heparin in rats. Drug Research 1986; 36: 1260–3.
   Google Scholar
• Douketis JD, Ginsberg JS, Burrows RF, Dukes EK, Webber EC, Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density. Thromb Haemost 1997; 75: 254–7.
   Google Scholar
• Dulitzki M, Pauzner R, Langevitz P, Pras M, Many A, Schiff E. Low molecular weight heparin during pregnancy and delivery – preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87: 380–3.
   Google Scholar
• Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39–43.
   Google Scholar
• Blombäck M, Bremme K, Hellgren M, Siegbahn A, Lindberg H. Thromboprophylaxis with low molecular mass heparin, ‘Fragmin’ (dalteparin), during pregnancy - a longitudinal safety study. Blood Coagul Fibrinolysis 1998; 9: 1–9.
   Google Scholar
• Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull 1998; 45: 320–3.
   Google Scholar
• Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263–8.
   Google Scholar
• Göpel W, Kim D, Gortner L. Prothrombotic mutations as a risk factor for preterm birth. Lancet 1999; 353: 1411–12.
   Google Scholar
• Sanson BJ, Lensing AWA, Prins MH, Ginsberg JS, Barka-gan ZS, Lavene-Pardonge E et al. Safety of low-molecularweight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668–72.
   Google Scholar
• Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL et al. Cancer risk in users of calcium channel blockers. Hypertension 1997; 29:1091–4.
   Google Scholar
• Kristensen J, Langhoff-Roos J, Skovgaard LT, Kristensen FB. Validation of the Danish birth registration. J Clin Epidemiol 1996; 49: 893–7.
   Google Scholar
• Sørensen HT. Regional administrative health registries as a resource in clinical epidemiology. Int J Risk Safety Med 1997; 10: 1–22.
   Google Scholar